They are C1 (NSCLC); C2, targeted therapy; C3, CML; C4, HER2; C5, pharmacokinetics; and C6, ALK (Table 4). The gene discussed is ALK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.